If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-25. Numbers and descriptions here follow the published literature rather than marketing material.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
In the 2011–12 season, a coaching change by appointing Christian Streich, with the club finishing 12th. Under Christian Streich, the 2012–13 Bundesliga season saw the club finish in fifth place, their best league standing since 1994–95. The fifth-place finish secured a position in the 2013–14 UEFA Europa League. Had Freiburg defeated Schalke 04 on the final matchday of the season, Freiburg would have advanced further in the league table against Schalke and qualified for the UEFA Champions League for the first time in club history. The 1–2 defeat to Schalke, however, saw Schalke secure fourth place in the league and qualify for the tournament instead. During the 2012–13 season, Freiburg also advanced to the semi-finals of the DFB-Pokal for the first time in the club's history, but lost to local rivals VfB Stuttgart 1–2, and missed the chance to play Bayern Munich in the final. In the 2014–15 season, after six years in the top flight, Freiburg was relegated to the 2. Bundesliga by a single point after a final-day defeat at Hannover 96. This was despite beating Bayern Munich in the second-last game. In the following season, however, the club earned its fifth promotion to the Bundesliga, with two matches to spare. The first season back in the Bundesliga saw them end seventh. This saw Freiburg qualify for the Europa League, as German cupwinners Borussia Dortmund were already qualified for the Champions League. The side were eliminated in the third qualification round against NK Domžale from Slovenia. Freiburg stayed in the top flight, finishing 15th.
Pizzeria Locale (2013–2023) was a fast casual pizza chain formed as a partnership with the original Pizzeria Locale restaurant in Boulder, Colorado. The chain grew to seven locations by 2017, but contracted after closing locations outside Colorado in 2018. Chipotle closed the remaining locations and dissolved the business in July 2023. The original Boulder restaurant, which was not owned by Chipotle, was renamed Pizzeria Alberico. Soul Daddy (May–June 2011) was a soul food fast casual restaurant managed by Chipotle. It operated three locations for less than five weeks before closing. ShopHouse Southeast Asian Kitchen (2011–2017) was an Asian fast-casual concept following the Chipotle service format. The chain grew to 15 locations before all were closed in March 2017. Tasty Made (2016–2018) was a burger restaurant concept. The sole location in Lancaster, Ohio, opened in October 2016 and closed in February 2018.
2C-B acts as a potent partial agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A and 5-HT2C receptors and to a lesser extent of the serotonin 5-HT2B receptor. In one study, it had EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values of 1.2 nM (101%) at the serotonin 5-HT2A receptor, 13 nM (97%) at the serotonin 5-HT2B receptor, and 0.63 nM (98%) at the serotonin 5-HT2C receptor. In earlier studies, 2C-B was found to be a low-efficacy serotonin 5-HT2A and 5-HT2C receptor partial agonist or even antagonist. However, subsequent studies have consistently found higher efficacy of 2C-B at these receptors. In addition to the serotonin 5-HT2 receptors, 2C-B also shows lower affinity for other serotonin receptors, such as the serotonin 5-HT1A and 5-HT1B receptors among others. However, while 2C-B itself was not assessed, other 2C derivatives showed little activity as serotonin 5-HT1A receptor agonists (EC50 = >3,000 nM). At the serotonin 5-HT2A receptor, 2C-B has subsequently been identified as a biased agonist, acting as a near-full agonist of receptor in terms of Ca2+ mobilization (EC50 = 1.64 nM; Emax = 92.6%) but with 6-fold lower potency as a moderate-efficacy partial agonist in terms of β-arrestin2 recruitment (EC50 = 10.0 nM; Emax = 60.1%). However, serotonin itself showed about 42-fold greater potency in activating Ca2+ mobilization than β-arrestin2 signaling in the study. The implications of the preceding findings are not fully clear.
detailed family history conducting a detailed physical examination to document morphological features testing for genetic defect in FGDY1 x-rays can identify skeletal abnormalities echo cardiogram can screen for heart abnormalities CT scan of the brain for cystic development X-ray of the teeth Ultrasound of abdomen to identify undescended testis Similar to all genetic diseases Aarskog–Scott syndrome cannot be cured, although numerous treatments exist to increase the quality of life. Surgery may be required to correct some of the anomalies, and orthodontic treatment may be used to correct some of the facial abnormalities. Trials of growth hormone have been effective to treat short stature in this disorder. Some people may have some mental slowness, but children with this condition often have good social skills. Some males may have problems with fertility. The syndrome is named for Dagfinn Aarskog, a Norwegian pediatrician and human geneticist who first described it in 1970, and for Charles I. Scott, Jr., an American medical geneticist who independently described the syndrome in 1971.
The typical nano-DESI probe setup consists of two fused silica capillaries – primary capillary, which supplies solvent and maintains a liquid bridge, and secondary capillary, which transports the dissolved analyte to the mass spectrometer. High voltage (several kV) is applied between the inlet of the mass spectrometer and the primary capillary, creating a self-aspirating nanospray. The liquid bridge is maintained by continuous flow of the solvent and the contact area between the solvent bridge and sample surface can be controlled by changing the solvent flow rate, varying the diameter of the utilized capillaries and regulating the distance between the sample and the nano-DESI probe. In this way, the spatial resolution in mass spectrometry imaging applications can be improved, with typical resolution ranging between 100–150 μm.
Sources: en.wikipedia.org
Immunity is determined genetically. Genomes in humans and animals encode the antibodies and numerous other immune response genes. While many of these genes are generally required for active and passive immune responses (see sections above), there are also many genes that appear to be required for very specific immune responses. For instance, Tumor Necrosis Factor (TNF) is required for defense of tuberculosis in humans. Individuals with genetic defects in TNF may get recurrent and life-threatening infections with tuberculosis bacteria (Mycobacterium tuberculosis) but are otherwise healthy. They also seem to respond to other infections more or less normally. The condition is therefore called Mendelian susceptibility to mycobacterial disease (MSMD) and variants of it can be caused by other genes related to interferon production or signaling (e.g. by mutations in the genes IFNG, IL12B, IL12RB1, IL12RB2, IL23R, ISG15, MCTS1, RORC, TBX21, TYK2, CYBB, JAK1, IFNGR1, IFNGR2, STAT1, USP18, IRF1, IRF8, NEMO, SPPL2A). The Center for Modeling Immunity to Enteric Pathogens (MIEP)
The use of RdRp plays a major role in RNA interference in eukaryotes, a process used to silence gene expression via small interfering RNAs (siRNAs) binding to mRNA rendering them inactive. Eukaryotic RdRp becomes active in the presence of dsRNA, and is less widely distributed than other RNAi components as it lost in some animals, though still found in C. elegans, P. tetraurelia, and plants. This presence of dsRNA triggers the activation of RdRp and RNAi processes by priming the initiation of RNA transcription through the introduction of siRNAs. In C. elegans, siRNAs are integrated into the RNA-induced silencing complex, RISC, which works alongside mRNAs targeted for interference to recruit more RdRps to synthesize more secondary siRNAs and repress gene expression. Spiegelman's Monster NS5B inhibitor RNA+Replicase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 2.7.7.48
36. Georgian Med News. 2006 Apr;(133):111-5. Anti-aging peptide bioregulators induce reactivation of chromatin. Lezhava T(1), Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Author information: (1)Tbilisi State University. The effect of synthetic peptide bioregulators (Epitalon, Livagen and Vilon) on structural and facultative heterochromatin of cultivated lymphocytes have been studied among old (75-88yr.) people. The data obtained indicate that epitalon, livagen and vilon: 1) activate synthetic processes, caused by reactivation of ribosomal genes as a result of deheterochromatinization (decondensation) of nucleolus organizer regions; 2) induce unrolling (deheterochromatinization) of total heterochromatin; 3) release genes repressed by heterochromatinization (condensation) of euchromatic regions forming facultative heterochromatin; 4) epitalon and livagen induce deheterochromatinization (decondensation) of pericentromeric structural heterochromatin of the chromosomes1 and 9. However, vilon does not induce deheterochromatinization of pericentromeric structural heterochromatin. These results indicate that peptide bioregulators Epitalon, Livagen and Vilon cause activation (deheterochromatinization) of chromatin in lymphocytes of old individuals.
Chemically, bismuth resembles arsenic and antimony, but is much less toxic. In almost all known compounds, bismuth has oxidation state +3; a few have states +5 or −3. The trioxide and trisulfide can both be made from the elements, although the trioxide is extremely corrosive at high temperatures. The pentoxide is not stable at room temperature, and evolves O2 gas if heated. Both oxides form complex anions, and NaBiO3 is a strong oxidising agent. The trisulfide is common in bismuth ore. Similarly, bismuth forms all possible trihalides, but the only pentahalide is BiF5. All are Lewis acids. Bismuth forms several formally BiI halides; these are complex salts with unusually structured polyatomic cations and anions.
Sources: en.wikipedia.org
the local conditions for initial crack growth which include the nucleation, growth, and coalescence of voids (decohesion) at a crack tip. a global energy balance criterion for further crack growth and unstable fracture.
A meta-analysis of randomized clinical trials (RCTs) reported that when consumed without any other antioxidant nutrient, the relative risk of heart attack was reduced by 18%. However, two large trials that were incorporated into the meta-analysis either did not show any benefit for heart attack, stroke, coronary mortality or all-cause mortality, or else a higher risk of heart failure in the alpha-tocopherol group. Vitamin E supplementation does not reduce the incidence of ischemic or hemorrhagic stroke. However, supplementation of vitamin E with other antioxidants reduced risk of ischemic stroke by 9% while increased the risk for hemorrhagic stroke by 22%.
==== Member of the Order of the British Empire (MBE) ==== Civil Division Inspector Joe Arukai. For services to the Royal Papua New Guinea Constabulary. Sister Joseph Mary Cresp. For services to charity. Bamaga Morre Imari. For services to the community, public service and the government. Justin Hansu Kill. For services to broadcasting. Sally Mokis. For services to the Papua New Guinea Banking Corporation. Membup Paril. For public services and services to the community. Cecilia Ropa. For services to health and the community. Noki Timbil. For services to the community.
The story ends with the poet writing of Akkad's fate, mirroring the words of the gods' curse earlier on: Its chariot roads grew nothing but the 'wailing plant, Moreover, on its canalboat towpaths and landings, No human being walks because of the wild goats, vermin, snakes, and mountain scorpions, The plains where grew the heart-soothing plants, grew nothing but the 'reed of tears, Akkad, instead of its sweet-flowing water, there flowed bitter water, Who said "I would dwell in that" found not a good dwelling place, Who said "I would lie down in Akkad" found not a good sleeping place.
== Bibliography == Bogle, James and Joanna. (1990). A Heart for Europe: The Lives of Emperor Charles and Empress Zita of Austria-Hungary, Fowler Wright, 1990, ISBN 0-85244-173-8 Brook-Shepherd, Gordon. (1991). The Last Empress: The Life and Times of Zita of Austria-Hungary 1893–1989. Harper-Collins. ISBN 0-00-215861-2 Harding, Bertita. (1939). Imperial Twilight: The Story of Karl and Zita of Hungary. Bobbs-Merrill Company Publishers. ASIN: B000J0DDQO (in German) Bernhard A. Macek: Kaiser Karl I. Der letzte Kaiser Österreichs. Ein biografischer Bilderbogen, Sutton Verlag, Erfurt 2012, ISBN 978-3-9540-0076-0 (in French) Debris, Cyrille. (2013). Zita, Portrait intime d'une imperatrice. Cerf, Paris, 2013, ISBN 978-2-204-10085-4
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.